Phase 1 N=8 Randomized Quadruple-blind Basic Science

Reinforcing Effects of Marijuana and Opioids

Marijuana Use · Opioid Use

Bottom Line

View on ClinicalTrials.gov: NCT05485012 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2026

Primary outcome: Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: Marijuana (Drug); Opioid (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Shanna Babalonis, PhD
Primary completion: Mar 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Self-Administration of Drug Units Earned	0.00; 3.83; 3.67; 0.00; 3.17; 3.00	—
SECONDARY Peak End-tidal Carbon Dioxide (EtCO2)	38.50; 39.17; 40.17; 43.50; 43.17; 45.50	—
SECONDARY Trough Respiration Rate	11.83; 12.17; 12.33; 10.33; 10.67; 10.83	—

Summary

The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.

Eligibility Criteria

Inclusion Criteria

Ages 18-50
Experience with marijuana and opioids
General good health
Willing to live at the University of Kentucky Hospital (research unit) for approx. 6.5 weeks (meals are provided,

Exclusion Criteria

Significant medical complications/conditions

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05485012). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.